5-甲基-5-苯基乙内酰脲 | 6843-49-8

• 物质功能分类: 有机原料 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 5-甲基-5-苯基乙内酰脲
• 中文别名: 5-甲基-5-苯基海因；5-甲基-5-苯海因
• 英文名称: 5-methyl-5-phenylimidazolidin-2,4-dione
• 英文别名: 5-methyl-5-phenylhydantoin；5-methyl-5-phenylimidazolidine-2,4-dione；4-Phenyl-4-methyl-2,5-dioxoimidazolidine
• CAS: 6843-49-8
• 化学式: C₁₀H₁₀N₂O₂
• mdl: MFCD00005265
• 分子量: 190.202
• InChiKey: JNGWGQUYLVSFND-UHFFFAOYSA-N

物化性质

• 熔点：
  199-201 °C (lit.)
• 沸点：
  325.7°C (rough estimate)
• 密度：
  1.2167 (rough estimate)
• 闪点：
  9℃
• 溶解度：
  DMSO（微溶）、乙醇（微溶）、甲醇（微溶）
• 保留指数：
  1866;1866

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22,R36
• 危险品运输编号：
  UN1230 - class 3 - PG 2 - Methanol, solution
• WGK Germany：
  3
• RTECS号：
  MU2625500
• 海关编码：
  2933990090
• 安全说明：
  S24/25
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  室温

SDS

Name:	5-Methyl-5-phenylhydantoin 99% Material Safety Data Sheet
Synonym:	2,4-Imidazolidinedione,5-methyl-5-phenyl
CAS:	6843-49-8

Section 1 - Chemical Product MSDS Name:5-Methyl-5-phenylhydantoin 99% Material Safety Data Sheet
Synonym:2,4-Imidazolidinedione,5-methyl-5-phenyl

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6843-49-8	5-methyl-5-phenylhydantoin	99.0	229-928-6

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Never give anything by mouth to an unconscious person. Get medical aid immediately.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Keep container closed when not in use. Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6843-49-8: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 199.00 - 201.00 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: N/A
Explosion Limits, upper: N/A
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10N2O2
Molecular Weight: 190.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, strong oxidants.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6843-49-8: MU2625500 LD50/LC50:
Not available.
Carcinogenicity:
5-methyl-5-phenylhydantoin - Not listed by ACGIH, IARC, or NTP.
Other:
See actual entry in RTECS for complete information.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 6843-49-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6843-49-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6843-49-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-5-苯基乙内酰脲 在 盐酸 、 铂 作用下， 生成 5-环己基-5-甲基咪唑烷-2,4-二酮
  参考文献：
  名称：

  Some 5,5-Disubstituted Hydantoins

  摘要：

  DOI：

  10.1021/ja01243a006
• 作为产物：
  描述：

  3-(tert-butyl)-1-(4-methoxybenzyl)-5-methyl-5-phenylimidazolidine-2,4-dione 在 甲烷磺酸 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成 5-甲基-5-苯基乙内酰脲
  参考文献：
  名称：

  Palladium Catalyzed C-Arylation of Amino Acid Derived Hydantoins

  摘要：

  Palladium(II) trifluoroacetate (5 mol %) catalyzes the C-arylation of N,N-disubstituted hydantoins by aryl iodides in good yield. The reaction proceeds through base-promoted enolization of the amino acid derived hydantoins, and the resulting 5,5-disubstituted hydantoins may be deprotected at one or both N atoms to yield biologically active structures or alternatively hydrolyzed to the parent a-aryl a-amino acids. The reaction is successful with a variety of parent amino acids and a range of electron-rich and electron-poor aryl iodides.

  DOI：

  10.1021/acs.orglett.5b01803

文献信息

• [EN] PROCESS FOR THE PREPARATION OF IODIDES<br/>[FR] PROCÉDÉ DE PRÉPARATION D'IODURES
  申请人：TECHNION R & D FOUNDATION LTD

  公开号：WO2011154953A1

  公开（公告）日：2011-12-15

  This invention is directed to a process for the preparation of high yield alkyl or aryl iodide from its corresponding carboxylic acid using N-iodo amides.

  这项发明涉及利用N-碘酰胺从相应的羧酸制备高产量的烷基或芳基碘化物的过程。
• Process for the preparation of chiral, nonracemic
  申请人：Hoechst Aktiengesellschaft

  公开号：US06018053A1

  公开（公告）日：2000-01-25

  The present invention relates to a process for the preparation of chiral, nonracemic compounds of the formula I ##STR1## in which R.sup.1 and R.sup.2 have the meanings indicated in claim 1 and which are useful intermediates for the preparation of pharmaceutical active compounds in which, for resolution, a salt is formed from the racemic compound of the formula I and a chiral, nonracemic amino compound. It furthermore relates to compounds of the formula I and esters thereof.

  本发明涉及一种制备手性、非拉克米化合物的方法，其化学式为I，在该化学式中，R.sup.1和R.sup.2具有权利要求书中指示的含义，并且它们是用于制备药用活性化合物的有用中间体，其中，为了分离，从化学式I的拉克米化合物和手性、非拉克米氨基化合物形成盐。此外，本发明还涉及化学式I及其酯化合物。
• LXR AGONISTS AND USES THEREOF
  申请人：Martinez Eduardo J.

  公开号：US20170066791A1

  公开（公告）日：2017-03-09

  This invention features compounds that modulate the activity of liver X receptors, pharmaceutical compositions including the compounds of the invention, and methods of utilizing those compositions for modulating the activity of liver X receptors in the treatment of cancer.

  这项发明涉及调节肝X受体活性的化合物，包括该发明的化合物的药物组合物，以及利用这些组合物调节肝X受体活性治疗癌症的方法。
• [EN] HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：ABBVIE INC

  公开号：WO2016044777A1

  公开（公告）日：2016-03-24

  Compounds having a structure of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R3c, R4a, R4b, R5, R6, Z and X are as defined herein are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

  提供具有公式I结构或其立体异构体、互变异构体或药学上可接受的盐的化合物，其中R1、R2a、R2b、R3a、R3b、R3c、R4a、R4b、R5、R6、Z和X如本文所定义。还提供包含这些化合物的药物组合物以及通过给予这些化合物治疗各种HAT相关病症或疾病，包括癌症的方法。
• Solution-phase synthesis and evaluation of tetraproline chiral stationary phases
  作者：Zhi Dai、Guozhong Ye、Charles U. Pittman、Tingyu Li

  DOI：10.1002/chir.22001

  日期：2012.4

  solution‐phase synthesis of multigram amounts of two 9‐fluorenylmethoxycarbonyl (Fmoc)‐protected tetraproline peptides. These tetraproline peptides were then attached to amino derivatized silica gel. The replacement of the Fmoc group with the trimethylacetyl group lead to two tetraproline chiral stationary phases (CSPs). A comparison of the chromatographic behavior of these two solution‐phase‐synthesized

  开发了一种协议方案，用于溶液相合成多克数量的两个9-芴基甲氧基羰基（Fmoc）保护的四脯氨酸肽。然后将这些四脯氨酸肽连接到氨基衍生的硅胶上。用三甲基乙酰基取代Fmoc基团会导致两个四脯氨酸手性固定相（CSP）。将这两种溶液相合成的四脯氨酸CSP与通过逐步固相合成制备的CSP的色谱行为进行比较，结果表明，这三种溶液均具有相似的色谱性能，可分离53种模型分析物。这表明寡聚脯氨酸的溶液相合成具有良好的批次重现性，选择器均质性以及可能的低成本等特定优势，是寡聚脯氨酸CSP固相合成的可行替代方法。手性，2012年。©2012 Wiley Periodicals，Inc.。

表征谱图